肝硬化肌少症与经颈静脉肝内门体分流术预后的关系

张帮婷; 胥莹; 杨雪芳; 张雪

doi:10.3969/j.issn.1001-5256.2021.12.041

肝硬化肌少症与经颈静脉肝内门体分流术预后的关系

DOI: 10.3969/j.issn.1001-5256.2021.12.041

昆明医科大学第二附属医院消化内科，昆明 650101

详细信息

通信作者:
胥莹，xuying_0505@163.com

中图分类号: R575.2
计量
- 文章访问数: 478
- HTML全文浏览量: 265
- PDF下载量: 43
- 被引次数: 0
出版历程
- 收稿日期: 2021-05-04
- 录用日期: 2021-05-24
- 出版日期: 2021-12-20

Association of sarcopenia with prognosis after transjugular intrahepatic portosystemic shunt in patients with liver cirrhosis

Department of Gastroenterology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China

摘要

摘要: 肌少症是肝硬化患者常见且隐匿的并发症，与肝硬化患者的预后密切相关。经颈静脉肝内门体分流术(TIPS)是治疗肝硬化门静脉高压相关并发症的重要手段。越来越多研究表明，肌少症与TIPS治疗肝硬化门静脉高压的预后有关。就国内外关于肌少症及其与TIPS的相关研究进行综述，以探究二者之间的关系，指导临床治疗。
- 肝硬化 /
- 肌减少症 /
- 门体分流术，经颈静脉肝内 /
- 预后
Abstract: Sarcopenia is a common and insidious complication in patients with liver cirrhosis and is closely associated with the prognosis of patients with liver cirrhosis. Transjugular intrahepatic portosystemic shunt (TIPS) is an important method for the treatment of portal hypertension-related complications. More and more studies have shown that sarcopenia is associated with the prognosis of cirrhotic portal hypertension after TIPS. This article reviews the research on sarcopenia and its association with TIPS in China and globally, in order to explore the association between them and guide clinical treatment.
- Liver Cirrhosis /
- Sarcopenia /
- Portasystemic Shunt, Transjugular Intrahepatic /
- Prognosis

HTML全文

参考文献(32)

[1]	KAMIMURA H, SATO T, NATSUI K, et al. Molecular mechanisms and treatment of sarcopenia in liver disease: A review of current knowledge[J]. Int J Mol Sci, 2021, 22(3): 1425. DOI: 10.3390/ijms22031425.
[2]	The Chinese College of Interventionalists. CCI clinical practice guidelines: Management of TIPS for portal hypertension (2019 edition)[J]. J Clin Hepatol, 2019, 35(12): 2694-2699. DOI: 10.3969/j.issn.1001-5256.2019.12.010. 中国医师协会介入医师分会. 中国门静脉高压经颈静脉肝内门体分流术临床实践指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2694-2699. DOI: 10.3969/j.issn.1001-5256.2019.12.010.
[3]	VIZZUTTI F, SCHEPIS F, ARENA U, et al. Transjugular intrahepatic portosystemic shunt (TIPS): Current indications and strategies to improve the outcomes[J]. Intern Emerg Med, 2020, 15(1): 37-48. DOI: 10.1007/s11739-019-02252-8.
[4]	NARDELLI S, LATTANZI B, TORRISI S, et al. Sarcopenia is risk factor for development of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement[J]. Clin Gastroenterol Hepatol, 2017, 15(6): 934-936. DOI: 10.1016/j.cgh.2016.10.028.
[5]	PRAKTIKNJO M, CLEES C, PIGLIACELLI A, et al. Sarcopenia is associated with development of acute-on-chronic liver failure in decompensated liver cirrhosis receiving transjugular intrahepatic portosystemic shunt[J]. Clin Transl Gastroenterol, 2019, 10(4): e00025. DOI: 10.14309/ctg.0000000000000025.
[6]	TSIEN C, SHAH SN, MCCULLOUGH AJ, et al. Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent[J]. Eur J Gastroenterol Hepatol, 2013, 25(1): 85-93. DOI: 10.1097/MEG.0b013e328359a759.
[7]	ARTRU F, MIQUET X, AZAHAF M, et al. Consequences of TIPSS placement on the body composition of patients with cirrhosis and severe portal hypertension: A large retrospective CT-based surveillance[J]. Aliment Pharmacol Ther, 2020, 52(9): 1516-1526. DOI: 10.1111/apt.16080.
[8]	ARTRU F, LABREUCHE J, LOUVET A. TIPSS and reversal of sarcopenia, and TIPSS is a promising therapy for sarcopenia in cirrhosis-Authors' reply[J]. Aliment Pharmacol Ther, 2021, 53(1): 211-212. DOI: 10.1111/apt.16152.
[9]	NASEER M, TURSE EP, SYED A, et al. Interventions to improve sarcopenia in cirrhosis: A systematic review[J]. World J Clin Cases, 2019, 7(2): 156-170. DOI: 10.12998/wjcc.v7.i2.156.
[10]	DENT E, MORLEY JE, CRUZ-JENTOFT AJ, et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, diagnosis and management[J]. J Nutr Health Aging, 2018, 22(10): 1148-1161. DOI: 10.1007/s12603-018-1139-9.
[11]	PÁR A, HEGYI JP, VÁNCSA S, et al. Sarcopenia - 2021: Pathophysiology, diagnosis, therapy[J]. Orv Hetil, 2021, 162(1): 3-12. DOI: 10.1556/650.2021.32015.
[12]	NISHIKAWA H, FUKUNISHI S, ASAI A, et al. Sarcopenia and frailty in liver cirrhosis[J]. Life (Basel), 2021, 11(5): 399. DOI: 10.3390/life11050399.
[13]	BOJKO M. Causes of sarcopenia in liver cirrhosis[J]. Clin Liver Dis (Hoboken), 2019, 14(5): 167-170. DOI: 10.1002/cld.851.
[14]	WEST J, GOW PJ, TESTRO A, et al. Exercise physiology in cirrhosis and the potential benefits of exercise interventions: A review[J]. J Gastroenterol Hepatol, 2021. DOI: 10.1111/jgh.15474.
[15]	NISHIKAWA H, SHIRAKI M, HIRAMATSU A, et al. Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria[J]. Hepatol Res, 2016, 46(10): 951-963. DOI: 10.1111/hepr.12774.
[16]	THANDASSERY RB, MONTANO-LOZA AJ. Role of nutrition and muscle in cirrhosis[J]. Curr Treat Options Gastroenterol, 2016, 14(2): 257-273. DOI: 10.1007/s11938-016-0093-z.
[17]	MEYER F, BANNERT K, WIESE M, et al. Molecular mechanism contributing to malnutrition and sarcopenia in patients with liver cirrhosis[J]. Int J Mol Sci, 2020, 21(15). DOI: 10.3390/ijms21155357.
[18]	HANAI T, SHIRAKI M, MIWA T, et al. Effect of loop diuretics on skeletal muscle depletion in patients with liver cirrhosis[J]. Hepatol Res, 2019, 49(1): 82-95. DOI: 10.1111/hepr.13244.
[19]	SINCLAIR M. Controversies in diagnosing sarcopenia in cirrhosis-moving from research to clinical practice[J]. Nutrients, 2019, 11(10): 2454. DOI: 10.3390/nu11102454.
[20]	ESLAMPARAST T, MONTANO-LOZA AJ, RAMAN M, et al. Sarcopenic obesity in cirrhosis-The confluence of 2 prognostic titans[J]. Liver Int, 2018, 38(10): 1706-1717. DOI: 10.1111/liv.13876.
[21]	DHALIWAL A, ARMSTRONG MJ. Sarcopenia in cirrhosis: A practical overview[J]. Clin Med (Lond), 2020, 20(5): 489-492. DOI: 10.7861/clinmed.2020-0089.
[22]	WANG Z, LIU FQ. Research advances in hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J]. J Clin Hepatol, 2019, 35(12): 2824-2827. DOI: 10.3969/j.issn.1001-5256.2019.12.040. 王重, 刘福全. 经颈静脉肝内门体分流术后肝性脑病的研究进展[J]. 临床肝胆病杂志, 2019, 35(12): 2824-2827. DOI: 10.3969/j.issn.1001-5256.2019.12.040.
[23]	PRAKTIKNJO M, BOOK M, LUETKENS J, et al. Fat-free muscle mass in magnetic resonance imaging predicts acute-on-chronic liver failure and survival in decompensated cirrhosis[J]. Hepatology, 2018, 67(3): 1014-1026. DOI: 10.1002/hep.29602.
[24]	GIOIA S, MERLI M, NARDELLI S, et al. The modification of quantity and quality of muscle mass improves the cognitive impairment after TIPS[J]. Liver Int, 2019, 39(5): 871-877. DOI: 10.1111/liv.14050.
[25]	BENMASSAOUD A, ROCCARINA D, ARICO F, et al. Sarcopenia does not worsen survival in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt for refractory ascites[J]. Am J Gastroenterol, 2020, 115(11): 1911-1914. DOI: 10.14309/ajg.0000000000000959.
[26]	ZOU SL, XU Y. Prognostic evaluation of transjugular intrahepatic portosystemic shunt in treatment of cirrhotic portal hypertension[J]. J Clin Hepatol, 2019, 35(1): 201-204. DOI: 10.3969/j.issn.1001-5256.2019.01.044. 邹松龙, 胥莹. 经颈静脉肝内门体分流术治疗肝硬化门静脉高压症的预后评估[J]. 临床肝胆病杂志, 2019, 35(1): 201-204. DOI: 10.3969/j.issn.1001-5256.2019.01.044.
[27]	MONTANO-LOZA AJ. Clinical relevance of sarcopenia in patients with cirrhosis[J]. World J Gastroenterol, 2014, 20(25): 8061-8071. DOI: 10.3748/wjg.v20.i25.8061.
[28]	SHOREIBAH MG, MAHMOUD K, ABOUELDAHAB NA, et al. Psoas muscle density in combination with model for end-stage liver disease score can improve survival predictability in transjugular intrahepatic portosystemic shunts[J]. J Vasc Interv Radiol, 2019, 30(2): 154-161. DOI: 10.1016/j.jvir.2018.10.006.
[29]	RONALD J, BOZDOGAN E, ZAKI IH, et al. Relative sarcopenia with excess adiposity predicts survival after transjugular intrahepatic portosystemic shunt creation[J]. AJR Am J Roentgenol, 2020, 214(1): 200-205. DOI: 10.2214/AJR.19.21655.
[30]	MONTANO-LOZA AJ, DUARTE-ROJO A, MEZA-JUNCO J, et al. Inclusion of sarcopenia within MELD (MELD-Sarcopenia) and the prediction of mortality in patients with cirrhosis[J]. Clin Transl Gastroenterol, 2015, 6: e102. DOI: 10.1038/ctg.2015.31.
[31]	LATTANZI B, NARDELLI S, PIGLIACELLI A, et al. The additive value of sarcopenia, myosteatosis and hepatic encephalopathy in the predictivity of model for end-stage liver disease[J]. Dig Liver Dis, 2019, 51(11): 1508-1512. DOI: 10.1016/j.dld.2019.09.004.
[32]	SINCLAIR M, CHAPMAN B, HOERMANN R, et al. Handgrip strength adds more prognostic value to the model for end-stage liver disease score than imaging-based measures of muscle mass in men with cirrhosis[J]. Liver Transpl, 2019, 25(10): 1480-1487. DOI: 10.1002/lt.25598.